The comparative analysis of the ISO 9001:2015 standard and Good Clinical Practice guidelines: the framework for improving management of clinical trials

The principal concept of the ICH Q8, Q9 and Q10 guidelines is to encourage implementation of scientific and systematic approaches for quality assurance of pharmaceutical products. Clinical trials, which are the crucially important part of the pharmaceutical research and development process, are outside of these guidelines, and it actualizes the issue on introducing quality management into clinical trials.

Aim. To analyze the ISO 9001 quality management methodology and the Addendum to GCP requirements in order to elaborate the methodical background for its combined use that will provide the effective work of the quality management system while achieving GCP compliance.

Materials and methods. The methods of the comparative analysis, synthesis, generalization, abstraction and content analysis were used to determine the possibility of ISO 9001:2015 and ICH GCP integration.

Results. The Addendum to GCP demonstrates the conformity of its provisions with prominent trends of quality management confirmed by the ISO 9001:2015 standard. The Addendum to GCP declares that the quality management system should use a risk-based approach, which allows conducting clinical trials more efficiently.

Conclusions. The ICH GCP framework can be easily and effectively integrated into the ISO 9001 quality management system of a particular clinical study, as well as in the entire system of quality assurance during the drug lifecycle. Further studies should be focused on development of the practical approaches and methods for implementation of the risk-based quality management in clinical trials.

Key words: clinical trials; quality management; risk management; good clinical practice; international standard organization
New challenges in the field of medical research lead to transformation of the basic approaches for quality assurance of pharmaceutical products. Introduction of the ICH Q8, Q9 and Q10 Guidelines allows building a unified science-based system, which covers the entire product lifecycle and is intended to improve the drug quality and efficiency of pharmaceutical manufacturing [1, 2]. The principal concept of these guidelines is to encourage implementation of scientific and systematic approaches for quality assurance of pharmaceutical products [3, 4]. It is widely acknowledged that clinical trials are the crucially important part of the pharmaceutical research and development process [5, 6]. But, they are outside the scope of these guidelines [1, 4, 7].

Nevertheless, the quality of the clinical development is an important issue since it provides scientific evidences about the principal properties of the drug quality – safety and efficiency [3, 6, 8]. Thus, the quality of the clinical stage of the drug development should be assured at the appropriate level in order to contribute to the entire quality system of pharmaceutical products [1, 9, 10].

The fundamental framework for providing quality by any organization is described in the ISO 9001 standard [11]. After 2015 revision of the ISO standard the risk-based approach was included into the quality management system. These changes were encouraged by the modern conditions related to the lack of resources, as well as simultaneous arising of the quality demands, and reflect the need for the efficiency increase [1, 4, 11].

The basic industry standard for performing clinical trials is Good Clinical Practice Guideline (GCP), which contains the requirements to study quality and perform its processes [12]. Following the risk-based innovative approaches and considering the existence of the pharmacy industry guideline for the Quality Risk Management ICH Q9 the GCP framework was also reviewed concerning the quality system, introduction of risk-based approaches and electronic data management [1, 3, 4, 8]. The first question arising while implementing quality management into clinical drug trials (CDT) is the possibility of the combined use of ISO 9001:2015 and GCP, as well as conformity of their requirements.

Thus, the aim of our study is a detail analysis and comparison of the ISO 9001:2015 quality management methodology and GCP requirements in order to elaborate the methodical background in the context of its consistent integration for enhancing of the clinical trials system.

Materials and methods

In order to examine the conformity of the ISO 9001:2015 and the Integrated Addendum to ICH E6 (R1) the comparative analysis of these documents was performed. Conclusions and recommendations concerning integration of the GCP framework...
into the ISO 9001:2015 quality management system were formulated using the methods of synthesis, generalization, abstraction and content-analysis.

**Results and discussion**

The Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2) contains critically important aspects and a fundamentally new approach relating to the quality management system within the clinical research [12]. Thus, a new version of GCP obliges the sponsor to implement the quality management throughout all stages of the clinical trial, including design, conduct, recording, evaluation, reporting and archiving of clinical trials. One of the main ideas of the new approach is proportionality of the methods used to assure and control the quality of the trial to risks inherent in the trial and the importance of the information collected.

To enhance implementation of the quality management standards into routine practice of clinical trials the analysis of particular paragraphs of the international standard ISO 9001:2015 and GCP provisions regarding the sponsor’s and investigator’s activities for the CDT quality assurance was conducted (Tab.). This comparison allows us to design the strategy of ISO requirements into the investigator’s activities, as well as the sponsor’s ones, and choose the strategy how to remove the main existing gaps for implementing the ISO 9001:2015 oriented management into the CDT practice [2, 4].

Such analysis helps to reveal specificity in performing the quality management functions by investigators and the sponsor. It also substantiates the importance of the quality management system building at a trial site since an independent structure is focused on specific goals that represent needs and expectations of stakeholders interacting

---

**The comparative analysis of the ISO 9001:2015 and the Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6 (R2) concerning clinical trial quality management**

<table>
<thead>
<tr>
<th>ISO 9001:2015</th>
<th>Addendum to the ICH E6(R1) paragraph concerning to</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4 Quality management system and its processes</td>
<td>The Sponsor’s Activity</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>4.0 Quality Management The sponsor should implement a system to manage quality throughout the design, conduct, recording, evaluation, reporting and archiving of clinical trials. Sponsors should focus on the trial activities that are essential to ensuring the subject protection and the reliability of trial results. Quality management includes the efficient design of clinical trial protocols, data collection tools and procedures, as well as the collection of information that is essential to decision making. The methods used to assure and control the quality of the trial should be proportionate to the risks inherent in the trial and the importance of the information collected. The sponsor should ensure that all aspects of the trial are operationally feasible and should avoid unnecessary complexity, procedures and data collection. Protocols, case report forms, and other operational documents should be clear, concise and consistent. 5.1.1 The sponsor is responsible for implementing and maintaining the quality assurance and the quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirement(s)</td>
<td>4.1.3 The investigator should be aware of, and should comply with, GCP and the applicable regulatory requirements</td>
</tr>
</tbody>
</table>
Continuation of Table 1

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3 Organizational roles, responsibilities and authorities</td>
<td>5.7 Responsibilities Prior to initiating a trial the sponsor should define, establish, and assign all trial-related duties and functions. The sponsor is responsible for securing agreement from all involved parties to ensure direct access to all trial related sites, the source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by domestic and foreign regulatory authorities</td>
<td>4.1.5 The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties. 4.2.5 The investigator is responsible for supervising any individual or party to whom the investigator delegates study tasks conducted at the trial site. 4.2.6 If the investigator/institution retains the services of any party to perform study tasks they should ensure this party is qualified to perform those study tasks and should implement procedures to ensure the integrity of the study tasks performed and any data generated</td>
</tr>
<tr>
<td>7.1.2 People</td>
<td>5.4.1 The sponsor should employ qualified individuals (e.g., biostatisticians, clinical pharmacologists, and physicians) as appropriate, throughout all stages of the trial process, from designing the protocol and CRFs and planning the analyses to analyzing and preparing interim and the final clinical trial reports</td>
<td>4.2.4 The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions</td>
</tr>
<tr>
<td>7.1.3 Infrastructure</td>
<td>5.6.1 The sponsor is responsible for selecting the investigator(s)/institution(s). Each investigator should be qualified by training and experience and should have adequate resources to properly conduct the trial for which the investigator is selected. If organization of a coordinating committee and/or selection of a coordinating investigator(s) are to be employed in multicentre trials, their organization and/or selection are the sponsor’s responsibility</td>
<td>4.2.1 The investigator should be able to demonstrate (e.g., based on retrospective data) a potential for recruiting the required number of suitable subjects within the recruitment period agreed. 4.2.3 The investigator should have available an adequate number of qualified staff and adequate facilities for the foreseen duration of the trial to conduct the trial properly and safely</td>
</tr>
<tr>
<td>7.2 Competence</td>
<td>5.3 Medical Expertise The sponsor should designate the appropriately qualified medical personnel who will be readily available to advise on the trial related medical questions or problems. If necessary, outside consultant(s) may be appointed for this purpose</td>
<td>4.1.1 The investigator(s) should be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial, should meet all the qualifications specified by the applicable regulatory requirement(s), and should provide evidence of such qualifications through up-to-date curriculum vitae and/or other relevant documentation requested by the sponsor, the IRB/IEC, and/or the regulatory authority(ies)</td>
</tr>
<tr>
<td>7.5.3 Control of the documented information</td>
<td>5.15.1 The sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) provide direct access to source data/documents for trial-related monitoring, audits, IRB/IEC review, and regulatory inspection</td>
<td>4.9.0 The investigator should maintain adequate and accurate source documents and trial records that include all pertinent observations on each of the site’s trial subjects. The source data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to the source data should be traceable, should not obscure the original entry and should be explained if necessary (e.g., via an audit trail)</td>
</tr>
</tbody>
</table>
during clinical trials while assuring high coordination and efficacy of the interaction.

In this way, the quality management system at a trial site, which is an important element of the clinical stage of drug development, can be easily integrated into the entire system of quality assurance that embraces all stages of the drug lifecycle [1, 3].

It should be underlined that 2015 version of the ISO standard contains an idea of risk-based thinking [11]. Thus, the risk assessment became an important part of planning the quality management system [4]. As a result, the preventive actions were replaced by actions to address risks and opportunities. In practical context this transforms the reactive quality management style to the pro-active one.

The implementation of this innovative approach by a new version of GCP elaborated in accordance with the ICH Q9 Guideline will allow applying the “improved and more efficient approaches to the clinical trial design, conduct, oversight, recording and reporting while continuing to ensure the human subject protection and data integrity”. The ICH GCP declares that the quality management system, which uses a risk-based approach, should have the following structure: 1) critical process and data identification, 2) risk identification, 3) risk evaluation, 4) risk control, 5) risk communication, 6) risk review, and 7) risk reporting [12].

Focus on risks described in detail in the Addendum to GCP demonstrates the conformity of its provisions with prominent trends of quality management set by the ISO 9001:2015 standard. The relevance of these issues encourages scholars and practitioners in the field of clinical trials to study the aspects of the risk-based management and quality assurance in clinical research and develop the corresponding knowledge-based methodical approaches.

CONCLUSIONS

The analysis has shown that the Integrated Addendum to ICH GCP E6 (R1) reflects all fundamental principles of quality management declared by ISO 9001:2015. That will provide the consistency between the revised version of GCP and ISO 9001:2015. After reviewing of GCP it can be easily and effectively integrated into the ISO 9001 quality management system due to the additional paragraph that describes the quality system development.

This initiates the new stage of clinical trial quality assurance built on modern concepts of quality management, and it is encompasses the risk-based approach. Thus, at the next stage the practical approaces and methods targeted on implementation of the risk-based quality management in clinical trials should be scientifically substantiated and elaborated. In our opinion, the special attention should be paid to description of the role of an investigator and a trial site within the whole quality management system of clinical trials and, particularly, at the stage of risk assessment and treatment.

Conflicts of Interests: authors have no conflict of interests to declare.
References


12. Risk-adapted approaches to the management of clinical trials of investigational medicinal products. – Available at: http://www.mhra.gov.uk/Howweregulate/Medicines/Licensing#medicines/Clinicaltrials/index.html

References


13. Risk-Adapted Monitoring in Clinical Trials. Summary Information by ECRIN (European Clinical Research Infrastructures Net-


Information about authors / Відомості про авторів / Информация об авторах

Dobrova V. Ye., Doctor of Pharmacy (Dr. habil.), professor of the Clinical Pharmacology and Clinical Pharmacy Department, National University of Pharmacy

Ратушная К. Л., кандидат медицинских наук, ассистент кафедры клинической фармакологии и клинической фармации, Национальный фармацевтический университет

Grintsov Ie. F., Candidate of Medicine (Ph.D.), associate professor of the Clinical Pharmacology and Clinical Pharmacy Department, National University of Pharmacy

Безугла Н. П., кандидат медицинских наук, доцент кафедры клинической фармакологии и клинической фармации, Национальный фармацевтический университет

Bezugla N. P., Candidate of Medicine (Ph.D.), associate professor of the Clinical Pharmacology and Clinical Pharmacy Department, National University of Pharmacy

Mailing address: 27, Pushkin'ska str., Kharkiv, 61057, Clinical Pharmacology and Clinical Pharmacy Department, National University of Pharmacy. +38 057 706 30 72. E-mail: clinpharm@nuph.edu.ua

Адрес для листування: 61057, м. Харків, вул. Пушкінська, 27, кафедра клінічної фармакології та клінічної фармації НФаУ. +38 057 706 30 72. E-mail: clinpharm@nuph.edu.ua

Надійшла до редакції 17.05.2017 р.